INTRODUCTION 1
First immunization studies in humans with viral vectors encoding vaccine antigens have 2 demonstrated induction of cellular and humoral immune responses (7, 20, 29, 30, 33) . Several 3 vector vaccines based on adenoviruses or poxviruses have shown promising preclinical results 4
and are currently at different stages of clinical development for prophylactic or therapeutic 5 use against infectious diseases or cancer. 6
In children, syringe and needle administration of vaccines faces acceptability problems, while 7 in developing countries inappropriate re-use of needles and syringes is associated with an 8 increased risk of infection. A non-invasive oral vaccination strategy could greatly facilitate 9 world-wide access to vaccines by for example enabling trained teachers to administer the 10 vaccine. So far, only live attenuated vaccines have been used for oral vaccination in humans. 11
The efficacy of these vaccines depends on subsequent replication and spread of the vaccines 12 in the gastro-intestinal tract. Although highly efficient, spread of live attenuated vaccines to 13 contact persons of the vaccinees or reversion of the vaccines to virulent forms limit the 14 applicability of the live attenuated vaccine approach for many infectious diseases. Oral 15 vaccination with replication-deficient viral vector vaccines might be able to substitute for the 16 live-attenuated vaccines, but it is questionable whether they can elicit substantial immune 17 responses given that the excess amount of antigens taken up as food on a regular basis mostly 18 leads to tolerance rather than immunity. In addition, if only the superficial layers of the through the epithelial barrier. Since the oral mucosa and, especially the crypt epithelium of 1 the tonsils are also rich of dendritic cells (DCs), delivery of the vaccine via the tonsillar crypts 2 could be a promising vaccination approach. 3
A C C E P T E D
Administering SIV onto the tonsils of rhesus macaques led to efficient infection of exposed 4 animals providing a valuable atraumatic mucosal challenge model (36). Tonsillar delivery of 5 live-attenuated SIV vaccines also provided protection against subsequent challenge with 6 homologous SIV and an SIV-HIV hybrid virus (35, 38) . Since protection induced by these 7 live-attenuated vaccines most likely has been due to systemic spread of the vaccine virus, we 8 now analysed the immunogenicity and efficacy of replication-deficient viral vector vaccines 9 after immunization by the tonsillar route and compared them to systemic administration. 10 Adenoviral vectors were selected for tonsillar immunizations, assuming that the natural 11 infection pathway of adenoviruses would also allow efficient delivery of the vector-encoded 12 vaccine antigens. For priming we also used a single-cycle immunodeficiency virus vaccine 13 (SCIV). The SCIVs were produced by transient transfection of an SIV genome, which was 14 made replication-deficient by mutations in the primer binding site and a deletion of vif. (23) . 15
To allow a single round of replication, the primer-binding site mutations were complemented 16 in trans by a matched tRNA expression plasmid in vif-independent 293 producer cells. After 17 administration to the vaccinees, the SCIVs can undergo only a single round of replication 18 leading to the production of non-infectious virus-like particles in vivo (12, 23) . To increase in
on October 3, 2017 by guest http://jvi.asm.org/ Downloaded from stimulus a pool of six 20-mer peptides derived from the gHCV NS3 gene (aa1138-1157, aa 23 1198-1217, aa 1208-1227, aa 1458-1477, aa 1528-1547, aa 1538-1557) limiting dilution format and a yield reduction assay for the determination of neutralising 1 antibodies (24) were employed. Recombinant SIVgp130 (EVA670, NIBSC) and SIVp27 2 (EVA643) for ELISA were kindly provided by Programme EVA. 3
Adenovirus-neutralizing antibodies known to be induced in vaccination regimes employing 4 adenoviral vectors were determined in a green fluorescent foci reduction assay as previously 5 described (14) with slight modifications. Briefly, inactivated monkey sera were analysed in 6 serial four-fold dilutions starting at a 1:8 dilution. 120 µl of diluted serum and 100 µl of a 7 replication-deficient Ad5 vector expressing EGFP containing 2x10 5 PFU were incubated in 8 triplicates at 4°C for 2h. Then 150µl of this mixture was transferred onto 96-well flat-bottom 9 plates which had been pre-seeded with 293 cells and the plates were incubated at 37°C in 5% 10 CO 2 for two days. Thereafter the plates were examined under a fluorescent microscope. 11
Sample dilutions exhibiting >50% reduction of green-fluorescent foci compared to infected 12 controls incubated with autologous monkey sera obtained before immunisation were 13 considered positive for Ad5 neutralising antibodies. Viral RNA copy numbers in plasma were 14 determined by real-time PCR as described (38) . 15
16

Statistical analyses 17
The mean number of spots per 10 6 PBMCs was determined from triplicate cultures for each 18 peptide pool and the mean number of spots in control cultures with an irrelevant HCV peptide 19 pool or lacking a peptide was subtracted. If data from several time points during the same 20 treatment period (e.g. prior to immunization, after 1 st , 2 nd , or 3 rd immunization) were 21 available the mean ELISPOTs were calculated for this period for each peptide pool and each 22
animal. The mean and standard deviation from each treatment period was determined for all 23 animals and each peptide pool within the same group. A One way ANOVA analysis followed 24 by pairwise multiple comparison using the Tukey Test was performed for each peptide pool to 25 test whether there is a significant difference in the ELISPOTs prior to immunization and after 26 each immunization. Significantly enhanced ELISPOT responses during immunization within 1 a treatment group were compared to the control group using the two-sided t-test. The t-test 2 (two-sided) was also used to analyse differences in the peak viral load, early early set point 3 RNA levels (mean of week 16, 20, and 24 of each animal), and late set point RNA levels 4 (mean of week 28 to 48). The Mann-Whitney Rank Sum Test was used to evaluate 5 differences in the median values of the log 2 antibody titers. 6 
A C C E P T E D
RESULTS 1
Adenoviral vector immunization by the tonsillar route 2
Given the tropism of adenoviruses of the subgenus C for the upper respiratory tract and their 3 persistence in submucosal lymphatic tissues, we first analysed whether a replication-deficient 4 adenoviral vector would allow expression of vaccine antigens in close proximity of the oral 5 MALT. A replication-deficient adenoviral vector expressing GFP was therefore sprayed 6 directly onto the tonsils of four rhesus monkeys. The adenoviral vector was administered at a 7 concentration of 2x10 11 particles/ml in total volume of 0.5 ml using a spray pump system 8 (Pfeiffer, Radolfzell, Germany). Since ketamin anaesthesia induced hypersalivation, monkeys 9
were treated with glycopyrroniumbromide 10 to 15 minutes prior to the oral spray application, 10 in order to enhance access of the vector preparations to the lymphoepithelium of the tonsils. 11
Two days later, immunohistological staining revealed GFP-positive cells with epithelial cell-12 like morphology at the basal cell layer of the squamous epithelium of the tonsils in three of 13 four animals. The close proximity to cells with lymphoid morphology (Fig. 1 A to some of the peptides used, non-immunized control animals were also analysed in the IFN-γ 1 ELISPOT assay. With the exception of the Env3 peptide pool, no significant differences 2 between the pre and mock values were detected in the control group (Fig. 2D) . Importantly, 3 the IFN-γ ELISPOT response to the Gag, p27, and Env2 peptide pool after the first, second 4 and/or third immunization was significantly higher in the orally immunized than in the non-5 immunized group (see arrows, Fig. 2C ). Thus, oral spray immunization with adenoviral 6 vectors induces cellular and humoral immune responses to the encoded vaccine antigen. 7 8
Challenge of monkeys immunized with adenoviral vectors by the oral route 9
The four monkeys receiving three oral immunizations with the adenoviral vector and eight 10 control monkeys were subsequently challenged orally with the SIVmac239 virus, a 11 neutralization-resistant molecular clone homologous to the vaccine antigens. An oral 12 challenge was performed, since this provides a reliable, truly atraumatic, mucosal infection 13 route (36). All animals became infected and peak viremia and set point RNA levels did not 14 differ significantly between these two groups (Fig. 2E) To improve efficacy of the tonsillar immunization against SIV, we investigated whether a 20 heterologous prime-boost regimen consisting of a SCIV prime and adenoviral vector boost 21 would be beneficial. In addition, we compared oral spray with systemic vaccine application 22 side by side. One group of four rhesus monkeys (systemic p/b) was immunized by priming 23 with SCIV at week 0 by the intravenous route and intramuscular boosting with the adenoviral 24 vectors encoding gag-pol, env, and rev at week 8 (Fig. 3) . A second group of four rhesus 25 monkeys (oral p/b) was immunized exclusively by spraying the vaccine preparations of SCIV 26 and the adenoviral vectors directly onto the tonsils of monkeys (Fig. 3) . For the oral 1 vaccination, each vaccine was given twice to compensate for the lower dose administered due 2 to volume restrictions. To control for unspecific immunostimulatory effects of the adenoviral 3 vector vaccines prior to challenge, two control monkeys each received an adenoviral vector 4 encoding GFP by either the oral (week 8 and 12) or the intramuscular (week 8) route. All 5 groups were challenged orally at week 20 with SIVmac239. 6 7 Systemic spread of SCIV transduced cells after oral immunization 8
A C C E P T E D
We previously observed systemic infection after oral exposure to replication competent SIV 9 (36) indicating that the tonsils provide a port of entry for SIV particles. To explore, whether 10 systemic spread would also occur after oral immunization with VSV-G pseudotyped 11 replication-deficient SCIVs, axillary lymph nodes were removed four days after 12 immunization and a highly sensitive in situ hybridisation technique was used to analyze 13 expression of SCIV. A low number of SIV RNA positive cells (1.87 RNA+ cells per section) 14 could be detected in the lymph nodes of 3 of the 4 immunized animals ( Fig. 1E-H 
Humoral immune responses 23
Priming with SCIV by the oral or intravenous route resulted in detectable antibodies to Gag in 24 only one animal from each group, while Env antibodies were detectable at low levels in two 25 animals after systemic immunization (Fig. 4) . After the two oral boosts with the adenoviral 26 vector an increase in Gag antibody titers was observed in all four animals and three of the 1 four animals also developed Env antibodies. After boosting the systemic vaccination group 2 with the adenoviral vector a sharp increase in antibody titers was observed, which exceeded 3 those seen after tonsillar immunization (Fig. 4) . The anti-Env antibodies induced in the 4 systemic group were able to neutralize the SIVmac251 strain, which had been used in the 5 neutralization assay due to the neutralization-resistant phenotype of the SIVmac239 virus, 6 while neutralizing antibodies in the oral p/b group remained undetectable (data not shown). 7 8
A C C E P T E D
Cellular immune responses 9
Cellular immune responses after immunization were monitored using the IFN-γ ELISPOT 10 assay (Fig. 5) . For statistical analyses, the mean of the ELISPOT response measured prior to 11 immunization (week -4 and 0) for each group was compared to the mean of the ELISPOT 12 response measured after priming ( week 4 and 8) and boosting (week 10 and 12). After oral 13 priming with SCIV, the ELISPOT response to the various peptide pools did not exceed the 14 background response seen prior to immunization. However, after the first boost with the 15 adenoviral vectors by the oral route a significant increase in the IFN-γ ELISPOT responses 16 after stimulation with the p27 and Env3 peptide pools was observed (Fig 5A) . Although 17 considerably higher mean ELISPOT numbers after boosting were also seen by stimulation 18 with the other peptide pools, this increase did not reach statistical significance. The systemic 19 prime-boost regimen induced a broad IFN-γ ELISPOT response to Gag, Rev, and various Env 20 peptide pools (Fig. 5B) . Side by side with the vaccinated animals, ELISPOT responses were 21 also measured for the control monkeys (Fig 5C) . With one exeption, there were no significant 22 differences between the boost values obtained for the control group and its pre values 23 excluding that a systematic error due to variations in culture conditions is responsible for the 24 positive ELISPOT responses seen after boosting in the vaccinated animals. A significant 25 change in the ELISPOT response of the control group was only observed for the Env3 peptide 26 peptide pool. Nevertheless, the increase in the Env3 IFN-γ ELISPOTs in the immunized 2 groups seems to be vaccine induced, since the number of ELISPOTS after boosting was 3 significantly lower in the control group than in the immunized groups. The ELISPOT 4 response to the p27CA peptide pool after the oral booster immunization was also significantly 5 higher than the ELISPOT response measured in parallel for the control group. Thus, the 6 ELISPOT response to these peptide pools after the oral prime boost immunization is 7 significantly higher than the preimmunization values of the same group and the ELISPOT 8 responses measured in parallel in the non-immunized control group. Using the same criteria 9 for the systemic SCIV prime adenoviral vector boost immunization a broader reactivity was 10 observed (see arrows, Fig. 5B ), with only two peptide pools not showing a statistically 11 significant ELISPOT response. 12 13
A C C E P T E D
Viral load after challenge 14
To investigate the efficacy of the oral prime-boost vaccination approach, monkeys were 15 challenged with SIVmac239 by the tonsillar route, thus providing a mucosal challenge with a 16 stringent form of SIV. All animals became infected (Fig. 6 ), but peak viral RNA load (week 17 2), early set point RNA levels (mean viral RNA load week 12 to 24), and late set-point RNA 18 levels (mean viral RNA load week 28 to 48) were 83, 35, and 43-fold lower, respectively in 19 orally immunized monkeys than in the control animals. The differences in peak viral load 20 between the two groups were statistically significant (p< 0.05). Of note, no differences in 21 viral load levels were observed between orally and systemically immunized monkeys. 22
23
Neutralizing antibodies against adenovirus 24
Antibody titers to SIV after oral immunization with the adenoviral vector vaccine increased 25 after the second administration (Fig. 2) . This implies that oral immunization with adenoviral 26 (Fig. 7) . A single 5 intramuscular injection of 6x10 11 adenoviral vector particles induced antibody titers exceeding 6 1/100 in all monkeys (Fig. 7B) . In contrast, a single oral immunization with 1x10 11 or 2x10 11 7 particles did not induces neutralizing antibodies, although high titered neutralizing antibodies 8 were detected after the oral booster immunization with the adenoviral vector (Fig. 7A, B) . 9
A C C E P T E D
However, the neutralizing antibody titers declined rapidly. A third oral immunization with the 10 adenoviral vectors 12 weeks after the second clearly boosted humoral immune responses to 11 SIV antigens, indicating that neutralizing antibodies to the adenoviral vector did not prevent 12 expression of the vaccine antigen after repeated oral administration. 13 
